Evidence map›Paper›PMID 41715181›Full record

ArticleArthritis research & therapy2026

Regional differences in clinical manifestations of antisynthetase syndrome: a comparison between Asian and European cohorts.

Tomoya Watanabe, Yasushi Ototake, Masako Tanaka, Hisho Kawamura, Izumi Moteki, Miwa Kanaoka, Yukie Yamaguchi

Abstract readComparative Study
In one paragraph

Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tomoya WatanabeDepartment of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. nabetomo@yokohama-cu.ac.jp.
Yasushi OtotakeDepartment of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Masako TanakaDepartment of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Hisho KawamuraDepartment of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Izumi MotekiDepartment of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Miwa KanaokaDepartment of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Yukie YamaguchiDepartment of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. yui1783@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-0297-6627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntisynthetase syndrome (ASyS) is an idiopathic inflammatory myopathy characterized by interstitial lung disease (ILD), mechanic’s hands, fever, arthritis, and Raynaud’s phenomenon. Although several domestic and international reports have described the clinical manifestations of ASyS, regional differences in clinical characteristics, including skin involvement, remain poorly understood. This study aimed to compare the regional differences in clinical features of ASyS by comparing data of Japanese patients with ASyS with those of previously published cohorts.

methodsWe conducted a retrospective chart review of 48 patients with ASyS at Yokohama City University Hospital between 2010 and 2024 and compared their data with those of previously published cohorts using univariate analysis. A literature review was performed using the PubMed database, with the search results limited to articles published between January 2010 and December 2024.

resultsThe mean age at onset was 56.5 ± 14.0 years, with a male-to-female ratio of 13:35. The prevalence of anti-Jo1 antibody was 35%. ILD and muscle weakness were observed in 97% and 52% of the patients, respectively. The most frequent skin involvement was Gottron’s sign (73%), followed by mechanic’s hands (65%) and periungual erythema (40%). A literature review using the same ASyS diagnostic criteria revealed that Asian cohorts, including ours, tend to have higher rates of ILD complications and a lower prevalence of anti-Jo1 antibodies than European cohorts. Furthermore, in the comparison of clinical manifestations with other Japanese and Asian cohorts, the rates of Raynaud’s phenomenon, muscle weakness, and malignant complications were nearly identical, although slight differences were observed in skin manifestations. By contrast, the European cohort was characterized by a high frequency of Raynaud’s phenomenon (39%), muscle weakness (85%), and anti-Jo1 antibody positivity (83%); meanwhile, ILD and mechanic’s hands were observed in 68% and 31%, respectively.

conclusionsThese results suggest that regional differences may exist in the clinical manifestations of ASyS, particularly in ILD prevalence, which may be linked to the underlying distribution of anti-aminoacyl transfer RNA synthetase antibody subtypes. A more detailed profiling of each antisynthetase antibody in a larger population is warranted to clarify these differences.

Indexed as

Asian PeopleEuropean PeopleMyositisAdultAgedAntibodies, AntinuclearCohort StudiesEuropeFemaleHumansJapanMaleMiddle AgedRetrospective StudiesAntibodies, AntinuclearAntisynthetase antibodyAntisynthetase syndromeClinical manifestationCohort studyRegional difference

Identifiers

PMID41715181
PMCPMC13032421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.